capecitabine has been researched along with Ascites, Gelatinous in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Baratti, D; Delfanti, S; Deraco, M; Di Bartolomeo, M; Galassi, M; Ghelardi, F; Greco, GF; Guaglio, M; Intini, R; Lampis, BR; Leoncini, G; Mazzoli, G; Milione, M; Morano, F; Nannini, M; Nasca, V; Pannone, A; Pietrantonio, F; Raimondi, A; Randon, G; Sabella, G | 1 |
| Antista, M; Baratti, D; Corallo, S; Cremolini, C; De Braud, F; Deraco, M; Di Bartolomeo, M; Guaglio, M; Kusamura, S; Marmorino, F; Milione, M; Morano, F; Niger, M; Pietrantonio, F; Raimondi, A; Randon, G | 1 |
| Beaty, K; Choe, JH; Eng, C; Fournier, KF; Mansfield, PF; Ohinata, A; Overman, MJ; Phillips, JK; Rafeeq, S; Royal, RE; Wolff, RA | 1 |
| Bagnoli, PF; Baratti, D; Berenato, R; Bossi, I; Busico, A; Caporale, M; de Braud, F; Deraco, M; Di Bartolomeo, M; Gloghini, A; Kusamura, S; Maggi, C; Mariani, L; Mennitto, A; Milione, M; Niger, M; Perrone, F; Pietrantonio, F; Settanni, G; Tamborini, E | 1 |
| Farquharson, AL; O'Dwyer, ST; Pranesh, N; Renehan, AG; Rout, S; Saunders, MP; Swindell, R; Taylor, MB; Wilson, MS; Witham, G | 1 |
| Denz, H; Fiegl, M; Gradl, J; Gratzl, M; Hutarew, G; Sun, WL | 1 |
| Brun, EA; Levitz, JS; Lichtman, SM; Sugarbaker, PH | 1 |
| Aravindan, N; Dang, A; Hightower, C; Ilsin, B; Mansfield, P; Rice, D; Riedel, B | 1 |
3 trial(s) available for capecitabine and Ascites, Gelatinous
| Article | Year |
|---|---|
Metronomic Capecitabine With Cyclophosphamide Regimen in Unresectable or Relapsed Pseudomyxoma Peritonei.
Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Cross-Over Studies; Cyclophosphamide; Female; Follow-Up Studies; Humans; Lymphocyte Count; Male; Middle Aged; Neutrophils; Progression-Free Survival; Prospective Studies; Pseudomyxoma Peritonei | 2019 |
GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study.
Topics: Administration, Metronomic; Aged; Bevacizumab; Biomarkers, Tumor; Capecitabine; Chromogranins; Disease-Free Survival; Female; Genome, Human; GTP-Binding Protein alpha Subunits, Gs; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Peritoneal Neoplasms; Prognosis; Pseudomyxoma Peritonei; Translational Research, Biomedical; Treatment Outcome | 2016 |
A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; CA-19-9 Antigen; Capecitabine; Carcinoembryonic Antigen; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Mitomycin; Peritoneal Neoplasms; Pseudomyxoma Peritonei; Quality of Life; Survival Rate; Treatment Outcome | 2008 |
5 other study(ies) available for capecitabine and Ascites, Gelatinous
| Article | Year |
|---|---|
Mytomicin-C, Metronomic Capecitabine, and Bevacizumab in Patients With Unresectable or Relapsed Pseudomyxoma Peritonei of Appendiceal Origin.
Topics: Appendiceal Neoplasms; Bevacizumab; Capecitabine; Disease Progression; Humans; Hyperthermia, Induced; Mitomycin; Peritoneal Neoplasms; Prospective Studies; Pseudomyxoma Peritonei | 2023 |
Improved Survival with Anti-VEGF Therapy in the Treatment of Unresectable Appendiceal Epithelial Neoplasms.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Bevacizumab; CA-19-9 Antigen; Camptothecin; Capecitabine; Carcinoembryonic Antigen; Carcinoma, Signet Ring Cell; Cetuximab; Cisplatin; Cytoreduction Surgical Procedures; Disease-Free Survival; ErbB Receptors; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Grading; Organoplatinum Compounds; Peritoneal Neoplasms; Pseudomyxoma Peritonei; Retrospective Studies; Survival Rate; Tumor Burden; Vascular Endothelial Growth Factor A | 2015 |
Successful antiangiogenic combination therapy for pseudomyxoma peritonei with bevacizumab and capecitabine.
Topics: Adenoma, Villous; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Bevacizumab; Capecitabine; Combined Modality Therapy; Deoxycytidine; Disease Progression; Fluorouracil; Hernia, Inguinal; Humans; Ileocecal Valve; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Peritoneal Neoplasms; Pseudomyxoma Peritonei; Treatment Outcome | 2009 |
Unusual abdominal tumors, case 1. Pseudomyxoma peritonei: response to capecitabine.
Topics: Abdominal Neoplasms; Adenocarcinoma, Mucinous; Appendiceal Neoplasms; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Male; Middle Aged; Pseudomyxoma Peritonei | 2004 |
Intraoperative hyperthermic intrathoracic chemotherapy for pleural extension of pseudomyxoma peritonei.
Topics: Adult; Anesthesia, General; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Humans; Hyperthermia, Induced; Intraoperative Period; Male; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Pleural Neoplasms; Pseudomyxoma Peritonei; Thoracic Surgical Procedures | 2007 |